{"jsonapi":{"version":"1.0"},"data":{"type":"recalls","id":"248f7d401ce001317b261095b8451ff652445069f270024972f72b0b87c45c61","attributes":{"feedName":"fda","feedSource":"fda","title":"Novitium Pharma Issues Voluntary National Recall of Ranitidine Hydrochloride Capsules 150mg and 300mg Due to an Elevated Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA)","description":"Voluntarily recalling all quantities and lots, within expiry, of Ranitidine Hydrochloride Capsules in the US to the consumer level. Ranitidine Hydrochloride Capsules are being recalled because of potential N-Nitrosodimethylamine (NDMA) amounts above levels established by the FDA.","link":"https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/novitium-pharma-issues-voluntary-national-recall-ranitidine-hydrochloride-capsules-150mg-and-300mg","publicationDate":"2019-10-25T21:36:40.000Z","state":"sent","affected":[],"allergens":[],"audience":["consumers"],"categories":["drugs"],"contaminants":["other"],"distribution":["AK","AL","AR","AZ","CA","CO","CT","DC","DE","FL","GA","HI","IA","ID","IL","IN","KS","KY","LA","MA","MD","ME","MI","MN","MO","MS","MT","NC","ND","NE","NH","NJ","NM","NV","NY","OH","OK","OR","PA","RI","SC","SD","TN","TX","UT","VA","VT","WA","WI","WV","WY"],"risk":"possible","token":"5db371988cec7f00015d702a"}}}